Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Fila, Marc" or (type any "bookEditor issueEditor" and editor="Fila, Marc")

Add to list
- Journal Article
- A1
- open access
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome

Larry A Greenbaum, Marc Fila, Gianluigi Ardissino, Samhar I Al-Akash, Jonathan Evans, Paul Henning, Kenneth V Lieberman, Silvio Maringhini, Lars Pape, Lesley Rees, et al.

(2016) KIDNEY INTERNATIONAL. 89(3). p.701-711
Add to list
A prospective study of paediatric patients with atypical haemolytic uraemic syndrom (aHUS) treated with eculuzumab : 1- year update

Lesley Reece, Larry A Greenbaum, Marc Fila, Gianluigi Ardissimo, Samhar Al-akash, Jonathan Evans, Kenneth Lieberman, Silvio Maringhini, Lars Pape, Nicole Van de Kar, et al.

(2015) PEDIATRIC NEPHROLOGY. 30(9). p.1564-1564
Add to list
- Conference Paper
- C3
- open access
Eculizumab (ECU) inhibits thrombotic microangiopathy (TMA) and improves renal function in pediatric patients (Pts) with atypical hemolytic uremic syndrome (aHUS)

Larry A Greenbaum, Marc Fila, Gianluigi Ardissino, Samhar I Al-Akash, Jonathan Evans, Paul Henning, Kenneth V Lieberman, Silvio Maringhini, Lars Pape, Lesley Rees, et al.

(2013) BLOOD. 122(21).
Add to list
- Conference Paper
- C3
- open access
Eculizumab inhibits thrombotic microangiopathy and improves renal function in pediatric patients with atypical hemolytic uremic syndrome

Larry Greenbaum, Marc Fila, Michel Tsimaratos, Gianluigi Ardissimo, Samhar I Al-Akash, Jonathan Evans, Paul Henning, Kenneth V Lieberman, Silvio Maringhini, Lars Pape, et al.

(2013) ASN Kidney Week, Abstracts.

Academic Bibliography

Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome

A prospective study of paediatric patients with atypical haemolytic uraemic syndrom (aHUS) treated with eculuzumab : 1- year update

Eculizumab (ECU) inhibits thrombotic microangiopathy (TMA) and improves renal function in pediatric patients (Pts) with atypical hemolytic uremic syndrome (aHUS)

Eculizumab inhibits thrombotic microangiopathy and improves renal function in pediatric patients with atypical hemolytic uremic syndrome

Contents

Support

Contact